Health Trials

A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

ConditionsPrimary Central Nervous System Lymphoma (PCNSL)Primary Central Nervous System LymphomaRelapsed Primary Central Nervous System LymphomaRefractory Primary Central Nervous System LymphomaCentral Nervous System LymphomaSecondary Central Nervous System LymphomaSecondary Central Nervous System Lymphoma (SCNSL)
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorMemorial Sloan Kettering Cancer Center

About this trial

The purpose of this study is to find out whether the combination of epcoritamab and ibrutinib is a safe treatment approach that causes few or mild side effects in people with relapsed/refractory primary central nervous system lymphoma (PCNSL) or secondary central nervous system lymphoma (SCNSL).

Eligibility criteria

Qualifiers

>/= 18 years of age on the day of consenting to the study.

Histologically documented DLBCL at enrolling institution (biopsy or CSF samples in PCNSL; biopsy of CNS or non-CNS sample in SCNSL)

Participants must have an ECOG performance status of 0, 1, or 2.

Absolute neutrophil count (ANC) ≥ 1 x 109/L

Disqualifiers

Newly diagnosed PCNSLs or SCNSLs and patients with non-CNS disease are excluded.

Patients with existing chronic moderate and severe hepatic impairment (Child-Pugh class B or C) are excluded

Patient is concurrently using other approved or investigational antineoplastic agents.

Patient has an active concurrent malignancy requiring active therapy

Trial design

Treatments tested in this trial

  • ibrutinib
  • Epcoritamab

Treatment groups

26 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Memorial Sloan Kettering Cancer Center

Lead sponsor

Source ClinicalTrials.gov